Overview: Post-Stimulation GH Levels TestIntroduction: The Post-Stimulation GH Levels Test measures growth hormone after stimulation to diagnose growth hormone deficiency, causing short stature or fatigue, helping guide treatment. Affecting 1 in 4,000 children, growth hormone deficiency poses diagnostic challenges due to subtle onset. Following 2023 Endocrine Society guidelines, it uses immunoassay for high accuracy, supporting endocrinology screening. This test is essential for diagnosis, treatment planning, and improving outcomes in pediatrics.
Other Names: Post-Stimulation GH Test, Growth Hormone Challenge Assay.
FDA Status: Laboratory-developed test (LDT), meeting endocrinology standards for diagnostic reliability.
Historical Milestone: Post-stimulation GH testing began in the 1960s with research by Roth, who developed stimulation protocols. Immunoassay advancements in the 1980s by Siemens improved detection, surpassing earlier bioassays.
Purpose: Measures growth hormone levels to diagnose growth hormone deficiency, guides hormone replacement therapy, and evaluates patients with short stature, aiming to promote growth.
Test Parameters: Growth hormone levels
Pretest Condition: Stimulation test required. Collect serum or plasma. Report history of growth issues.
Specimen: Serum (SST, 2-5 mL), Plasma (EDTA, 2-4 mL); 2 mL serum in SST. Transport in a biohazard container.
Sample Stability at Room Temperature: 6 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document short stature or fatigue. Include current medications or family history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., metabolic issues), and sample collection risks.
Procedural Considerations: Uses immunoassay to measure levels, requiring labs with analyzers. Results available in 1-2 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample hemolysis or improper stimulation can affect results. Medications may alter levels, requiring correlation.
Clinical Significance: Low levels suggest growth hormone deficiency, guiding therapy. Early treatment might promote growth, while untreated cases lead to short stature. Normal levels may require other tests.
Specialist Consultation: Consult an endocrinologist for interpretation.
Additional Supporting Tests: IGF-1 levels, bone age X-ray, or MRI to confirm diagnosis.
Test Limitations: Specific to stimulation response; correlation with clinical status needed. False negatives possible with mild deficiency.
References: Endocrine Society Guidelines, 2023; Journal of Clinical Endocrinology & Metabolism, Roth J, 2022.
